In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer

Abstract Poly ADP-ribose polymerase (PARP) inhibitors are promising targeted therapy for epithelial ovarian cancer (EOC) with BRCA mutations or defective homologous recombination (HR) repair. However, reversion of BRCA mutation and restoration of HR repair in EOC lead to PARP inhibitor resistance an...

Full description

Bibliographic Details

Published in:	Scientific Reports
Main Authors:	Z. Ping Lin, Nour N. Al Zouabi, Mark L. Xu, Nicole E. Bowen, Terence L. Wu, Ethan S. Lavi, Pamela H. Huang, Yong-Lian Zhu, Baek Kim, Elena S. Ratner
Format:	Article
Language:	English
Published:	Nature Portfolio 2021-04-01
Online Access:	https://doi.org/10.1038/s41598-021-87325-5